| Q44345218 | 14 beta-Chlorocinnamoylamino derivatives of metopon: long-term mu-opioid receptor antagonists |
| Q24676532 | 1‐Hydroxy‐3‐amino‐pyrrolidone‐2 (HA‐966): a new GABA‐like compound, with potential use in extrapyramidal diseases |
| Q50750285 | 2-Phenylethynyl-butyltellurium attenuates amyloid-β peptide(25-35)-induced learning and memory impairments in mice. |
| Q36159201 | 3-Iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in mice |
| Q38738600 | 4-methyl benzylamine stimulates food consumption and counteracts the hypophagic effects of amphetamine acting on brain Shaker-like Kv1.1 channels |
| Q60734987 | 5-HT1A Agonists Induce Central Cholinergic Antinociception |
| Q51192816 | A Possible Enzyme Barrier for γ-Aminobutyric Acid in the Central Nervous System |
| Q43773926 | A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis. |
| Q37107564 | A novel Gbetagamma-subunit inhibitor selectively modulates mu-opioid-dependent antinociception and attenuates acute morphine-induced antinociceptive tolerance and dependence |
| Q48943450 | A possible mechanism of the tyramine-induced head-twitch response |
| Q34420509 | A potent and selective endogenous agonist for the mu-opiate receptor |
| Q48271701 | A potential role for the secretogranin II-derived peptide EM66 in the hypothalamic regulation of feeding behaviour |
| Q37115330 | A prolonged nitric oxide-dependent, opioid-mediated antinociceptive effect of hyperbaric oxygen in mice |
| Q45040805 | A rapid method for the verification of drug injection into the cerebral ventricular system of the rat |
| Q39432376 | A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice |
| Q37523119 | A spider derived peptide, PnPP-19, induces central antinociception mediated by opioid and cannabinoid systems |
| Q42856063 | A study of central opioid receptor involvement in nitrous oxide analgesia in mice. |
| Q60734912 | AG-4: a nicotinic agonist endowed with antiamnesic properties |
| Q39399681 | Acetyl-l-carnitine induces muscarinic antinocieption in mice and rats |
| Q54056110 | Activation of central ATP-sensitive potassium channels produces the antinociception and spinal noradrenaline turnover-enhancing effect in mice. |
| Q41967216 | Activities of narcotic and narcotic-antagonist analgesics following the intraventricular injection of various substances. |
| Q77982381 | Adenosine-angiotensin II interactions in pentylenetetrazol seizure threshold in mice |
| Q44348607 | Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan. |
| Q28588212 | Aminophosphinic inhibitors as transition state analogues of enkephalin-degrading enzymes: a class of central analgesics |
| Q53379775 | Amyloid-β peptide absence in short term effects on kinase activity of energy metabolism in mice hippocampus and cerebral cortex. |
| Q72579627 | An ATP-sensitive potassium channel blocker abolishes the potentiating effect of morphine on the bicuculline-induced convulsion in mice |
| Q51247129 | An autoradiographic study of the incorporation of nucleic-acid precursors by neurones and glia during nerve regeneration |
| Q51247122 | An autoradiographic study of the incorporation of nucleic-acid precursors by neurones and glia during nerve stimulation |
| Q40001159 | An investigation of the tachycardia produced by intracerebro-ventricular injections of isoprenaline in mice |
| Q39196952 | Analgesia and motor activity elicited by morphine and enkephalins in two inbred strains of mice |
| Q36407454 | Analgesic activity of the naturally occurring heptapeptide [Met]enkephalin-Arg6-Phe7. |
| Q44351665 | Analgesic cross-tolerance between morphine and opioid peptides |
| Q51838331 | Analgesic effect of histamine induced by intracerebral injection into mice. |
| Q44344629 | Analgesic effects of Tyr-W-MIF-1: a mixed mu2-opioid receptor agonist/mu1-opioid receptor antagonist |
| Q76428359 | Antagonism against the arecoline tremors of oxyphenonium and its tertiary analogue after intravenous and intracerebral administration in mice |
| Q35227360 | Antagonism by physostigmine of the "running fit" caused by levorphanol, a morphine congener, in mice |
| Q44317540 | Antagonism of nitrous oxide-induced anxiolytic-like behavior in the mouse light/dark exploration procedure by pharmacologic disruption of endogenous nitric oxide function |
| Q37464254 | Antagonism of the antinociceptive effect of nitrous oxide by inhibition of enzyme activity or expression of neuronal nitric oxide synthase in the mouse brain and spinal cord |
| Q44335960 | Antagonism of the morphine-induced Straub tail reaction by kappa-opioid receptor activation in mice |
| Q70220149 | Anti-anaphylactic action in the mouse of thyrotropin-releasing hormone (TRH) is mediated through β1-adrenoceptive effectors |
| Q66961777 | Anti-nociceptive activity of narcotic agonists and partial agonists in mice given biogenic amines by intracerebroventricular injection |
| Q47997135 | Antiamnesic action of cromakalim, a potassium channel opener, in mice treated with hypoxia- and cerebral ischemia-type stress stimuli |
| Q59242596 | Antiamnesic effect of the two novel ?-opioid agonists, VA-100 and VA-101, in the mouse passive avoidance test |
| Q42751162 | Antibodies and antisense oligodeoxynucleotides to mu-opioid receptors, selectively block the effects of mu-opioid agonists on intestinal transit and permeability in mice. |
| Q46834558 | Anticonvulsant and anxiolytic-like effects of compounds isolated from Polygala sabulosa (Polygalaceae) in rodents: in vitro and in vivo interactions with benzodiazepine binding sites. |
| Q73193801 | Anticonvulsive activity of a new GABA mimetic drug |
| Q43181992 | Antidepressant-like effects of endogenous histamine and of two histamine H1 receptor agonists in the mouse forced swim test |
| Q67019753 | Antidiuretic effect of morphine and vasopressin in morphine tolerant and non-tolerant rats, differential effects on urine composition |
| Q38290599 | Antihistamine antinociception is mediated by Gi-protein activation. |
| Q70865314 | Antinociceptive activities of non-steroidal antiinflammatory drugs (NSAIDs) following intracerebroventricular (i.c.v.) and intrathecal (i.t.) administration in mice |
| Q48690476 | Antinociceptive and gastrointestinal effects of opiates: an analysis of the nature of the involvement of mu and delta receptors of the central nervous system in morphine-tolerant and non-tolerant mice |
| Q48231577 | Antinociceptive evaluation of 14β-(bromoacetamido)- 7,8-dihydro-N(cyclopropylmethyl)-normorphinone in mice |
| Q47811552 | Antinociceptive interaction between alprazolam and opioids |
| Q59242598 | Antinociceptive profile of the natural cholinesterase inhibitor huperzine A |
| Q60735005 | Antinociceptive profile of the new nicotinic agonist DBO-83 |
| Q60735009 | Antinociceptive property of the nicotinic agonist AG-4 in rodents |
| Q48224953 | Antisense 'knockdowns' of M1 receptors induces transient anterograde amnesia in mice |
| Q44407080 | Antisense knockdown of the Shaker-like Kv1.1 gene abolishes the central stimulatory effects of amphetamines in mice and rats |
| Q44288260 | Atropine reverses the antinociception of nonsteroidal anti-inflammatory drugs in the tail-flick test of mice |
| Q42667921 | Behavioral effects of urotensin-II centrally administered in mice |
| Q67300699 | Behavioural supersensitivity to apomorphine following cerebral dopaminergic denervation by 6-hydroxydopamine |
| Q36365338 | Beta-Endorphin: dissociation of receptor binding activity from analgesic potency |
| Q43001090 | Biogenic amines and head twitches in mice during ethanol withdrawal |
| Q48660666 | Blockade of clomipramine and amitriptyline analgesia by an antisense oligonucleotide to mKv1.1, a mouse Shaker-like K+ channel. |
| Q52550044 | Blockade of glutamate- and cholinergic ion channels by amantadane derivatives. |
| Q49053717 | Brain barbital levels and anesthesia as influenced by physostigmine and epinephrine |
| Q52231263 | Brain catecholamines modifications. The effects on memory facilitation induced by oxotremorine in mice. |
| Q44293185 | Buspirone-induced antinociception is mediated by L-type calcium channels and calcium/caffeine-sensitive pools in mice |
| Q42712495 | CGP 35348, a new GABAB antagonist, prevents antinociception and muscle-relaxant effect induced by baclofen |
| Q41877459 | CRF receptor 1 antagonism and brain distribution of active components contribute to the ameliorative effect of rikkunshito on stress-induced anorexia. |
| Q69011075 | Calcium channel involvement in magnetic field inhibition of morphine-induced analgesia |
| Q58732614 | Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor |
| Q28361058 | Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation |
| Q37091405 | Central administration of angiotensin IV rapidly enhances novel object recognition among mice |
| Q34807215 | Central amygdala glucocorticoid receptor action promotes fear-associated CRH activation and conditioning |
| Q43263874 | Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. |
| Q44944176 | Central and peripheral visceral effects of bombesin |
| Q41782285 | Central antinociception induced by mu-opioid receptor agonist morphine, but not delta- or kappa-, is mediated by cannabinoid CB1 receptor |
| Q48729296 | Central corticotropin-releasing factor and benzodiazepine receptor systems are involved in the social isolation stress-induced decrease in ethanol sleep in mice |
| Q48835658 | Central effects of 5-hydroxytryptamine and noradrenaline on body temperature and oxygen consumption in infant rats |
| Q42075715 | Central injection of nitric oxide synthase inhibitors increases peripheral interleukin-6 and serum amyloid A: involvement of adrenaline from adrenal medulla |
| Q35044444 | Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test |
| Q67376424 | Central neurotoxicity of apamin, crotamin, phospholipase A and α-amanitin |
| Q66966268 | Centrally and peripherally mediated inhibition of intestinal motility by opioids |
| Q46746202 | Centrally mediated antihyperalgesic and antiallodynic effects of zonisamide following partial nerve injury in the mouse |
| Q40154231 | Centrally mediated effects of neurohypophyseal hormones |
| Q44351419 | Characterization of mechanical withdrawal responses and effects of mu-, delta- and kappa-opioid agonists in normal and mu-opioid receptor knockout mice |
| Q48827215 | Characterization of temporal expressions of FOXO and pFOXO proteins in the hippocampus by kainic acid in mice: involvement of NMDA and non-NMDA receptors |
| Q73327845 | Cholecystokinin-induced antinociception is not blocked by CCK-A or CCK-B receptor antagonists |
| Q48392103 | Chronic curcumin treatment normalizes depression-like behaviors in mice with mononeuropathy: involvement of supraspinal serotonergic system and GABAA receptor |
| Q36437508 | Ciliary neurotrophic factor inhibits brain and peripheral tumor necrosis factor production and, when coadministered with its soluble receptor, protects mice from lipopolysaccharide toxicity. |
| Q41485665 | Cilostazol prevents amyloid β peptide25‐35‐induced memory impairment and oxidative stress in mice |
| Q43693380 | Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum |
| Q24597777 | Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeys |
| Q79991386 | Codeine and 6-acetylcodeine analgesia in mice |
| Q50617700 | Cognitive effects of vanillic acid against streptozotocin-induced neurodegeneration in mice. |
| Q43722675 | Comparison of N2O- and chlordiazepoxide-induced behaviors in the light/dark exploration test |
| Q41770025 | Comparison of antinociception induced by supraspinally administered L-arginine and kyotorphin |
| Q28340819 | Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice |
| Q37613022 | Complete differentiation between enkephalinase and angiotensin-converting enzyme inhibition by retro-thiorphan |
| Q28654400 | Correlations of amyloid-β concentrations between CSF and plasma in acute Alzheimer mouse model |
| Q44330476 | Cross-tolerance between analgesia produced by xylazine and selective opioid receptor subtype treatments. |
| Q40215211 | Cyclic nucleotide concentrations in the brains of mice treated with the convulsant bicyclic organophosphate, 4-isopropyl-2,6,7-trioxa-1 -phosphabicyclo[2,2,2] octane |
| Q24645923 | Deltorphin transport across the blood-brain barrier |
| Q67019750 | Development of cellular tolerance to lethality and analgesia concurrent with physical dependence following repeated oral administration of LAAM |
| Q42371109 | Dexamethasone-induced selective inhibition of the central mu opioid receptor: functional in vivo and in vitro evidence in rodents. |
| Q37362925 | Diet-induced obese mice develop peripheral, but not central, resistance to leptin |
| Q70770700 | Difference in the development of tolerance to morphine and d-ala2-methionine-enkephalin in C57 BL/6J and DBA/2J mice |
| Q44336916 | Different types of opioid receptors mediating analgesia induced by morphine, DAMGO, DPDPE, DADLE and beta-endorphin in mice |
| Q53435148 | Differential cross-tolerance development between single and repeated immobilization stress on the antinociceptive effect induced by β-endorphin, 5-hydroxytryptamine, morphine, and WIN55,212-2 in the inflammatory mouse pain mode. |
| Q72344505 | Differential effect of glucocorticoids on tumour necrosis factor production in mice: up-regulation by early pretreatment with dexamethasone |
| Q73118039 | Differential modulation by muscimol and baclofen on antinociception induced by morphine, beta-endorphin, D-Pen2,5-enkephalin and U50,488H administered intracerebroventricularly in the mouse |
| Q28364877 | Differential prevention of morphine amnesia by antisense oligodeoxynucleotides directed against various Gi-protein alpha subunits |
| Q38348084 | Diphenhydramine-induced amnesia is mediated by Gi-protein activation |
| Q34483780 | Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. |
| Q44308553 | Dopamine D1 receptor signaling system regulates ryanodine receptor expression in ethanol physical dependence |
| Q49843389 | Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson's disease-like motor dysfunction |
| Q41058585 | Dysfunctional GPR40/FFAR1 signaling exacerbates pain behavior in mice |
| Q73670985 | Effect of 7-nitroindazole on tolerance to morphine, U-50,488H and [D-Pen2, D-Pen5] enkephalin in mice |
| Q28340913 | Effect of ICV taurine on the impairment of learning, convulsions and death caused by hypoxia |
| Q51540550 | Effect of K+ channel modulation on mouse feeding behaviour. |
| Q40094581 | Effect of benzodiazepines on central serotonergic neuron systems |
| Q48560843 | Effect of chronic administration of [D-Pen2, D-Pen5] enkephalin on the activity of nitric oxide synthase in brain regions and spinal cord of mice |
| Q44338130 | Effect of chronic ethanol treatment on μ-opioid receptor function, interacting proteins and morphine-induced place preference |
| Q58133827 | Effect of histamine receptors agonists or antagonists administered intracerebroventricularly and intrathecally on the blood glucose level in immobilization stress model |
| Q67462840 | Effect of intracerebroventricular 5,6-dihydroxytryptamine on blood pressure of spontaneously hypertensive rats |
| Q71562892 | Effect of nitric oxide synthase inhibition on tolerance to the analgesic action of D-Pen2, D-Pen5 enkephalin and morphine in the mouse |
| Q43190830 | Effect of potassium channel modulators in mouse forced swimming test |
| Q48254264 | Effect of pretreatment with pertussis toxin on the development of physical dependence on morphine |
| Q68162835 | Effect of serotoninergic drugs on stress-induced hyperthermia (SIH) in mice |
| Q44347403 | Effect of supraspinal antisense oligodeoxynucleotide treatment on delta-opioid receptor mRNA levels in mice |
| Q48152760 | Effects of 5,7-dihydroxytryptamine and 6-hydroxydopamine on head-twitch response induced by serotonin, p-chloroamphetamine, and tryptamine in mice |
| Q48078497 | Effects of Agmatine on Depressive-Like Behavior Induced by Intracerebroventricular Administration of 1-Methyl-4-phenylpyridinium (MPP(+)). |
| Q44347309 | Effects of NMDA receptor antagonists on delta1- and delta2-opioid receptor agonists-induced changes in the mouse brain [3H]DPDPE binding |
| Q33934425 | Effects of Uncaria tomentosa total alkaloid and its components on experimental amnesia in mice: elucidation using the passive avoidance test |
| Q67486202 | Effects of [D-Ala2, D-Leu5]enkephalin and [D-Pen2, L-Pen5]enkephalin on apomorphine-induced motor activity in the mouse |
| Q43796454 | Effects of angiotensin III and angiotensin IV on pentylenetetrazol seizure susceptibility (threshold and kindling): interaction with adenosine A(1) receptors |
| Q35739771 | Effects of betaine on lipopolysaccharide-induced memory impairment in mice and the involvement of GABA transporter 2. |
| Q48420760 | Effects of centrally administered H2 antagonists in the behavioral despair test |
| Q35884593 | Effects of competitive and noncompetitive antagonists of the N-methyl-D-aspartate receptor on the analgesic action of delta 1- and delta 2-opioid receptor agonists in mice |
| Q35176148 | Effects of drugs affecting endogenous amines or cyclic nucleotides on ethanol withdrawal head twitches in mice |
| Q36588384 | Effects of elevated calcium and calcium antagonists on 6,7-benzomorphan-induced analgesia |
| Q41203727 | Effects of erythropoietin on memory deficits and brain oxidative stress in the mouse models of dementia |
| Q28363252 | Effects of ganglion blocking agents on nicotine extensor convulsions and lethality in mice |
| Q44345442 | Effects of ibogaine and noribogaine on the antinociceptive action of mu-, delta- and kappa-opioid receptor agonists in mice |
| Q44345449 | Effects of ibogaine on the development of tolerance to antinociceptive action of mu-, delta- and kappa-opioid receptor agonists in mice |
| Q72828370 | Effects of intrathecal or intracerebroventricular pretreatment with pertussis toxin on antinociception induced by beta-endorphin or morphine administered intracerebroventricularly in mice |
| Q44344579 | Effects of morphine-3-glucuronide on the antinociceptive activity of peptide and nonpeptide opioid receptor agonists in mice |
| Q44345005 | Effects of multiple intracerebroventricular injections of [D-Pen2,D-Pen5]enkephalin and [D-Ala2,Glu4]deltorphin II on tolerance to their analgesic action and on brain delta-opioid receptors |
| Q93136416 | Effects of resveratrol and oxyresveratrol on hippocampal cell death induced by kainic acid |
| Q44346259 | Effects of some 7-arylidene and 7-heteroarylidene morphinan-6-ones on the antinociceptive activity of [D-Pen2, D-Pen5]enkephalin and [D-Ala2, Glu4]deltorphin II and on multiple opioid receptors |
| Q72913155 | Effects of ß-Endorphin on body temperature in mice at different ambient temperatures |
| Q35177657 | Enhancement of a nociceptive reaction by opioid antagonists in mice |
| Q44343222 | Enhancement of blood-brain barrier permeability to sodium fluorescein by stimulation of mu opioid receptors in mice |
| Q39122695 | Enhancement of ethanol-induced withdrawal convulsions by blockade of 5-hydroxytryptamine receptors |
| Q41489647 | Evidence for a cholinergic role in haloperidol-induced catalepsy |
| Q71611832 | Evidence for central histaminergic mechanism in foot shock aggression |
| Q77152158 | Evidence for hypernociception induction following histamine H1 receptor activation in rodents |
| Q35169472 | Fisetin exerts antihyperalgesic effect in a mouse model of neuropathic pain: engagement of spinal serotonergic system |
| Q48726235 | Flumazenil but not FG7142 reverses the decrease in pentobarbital sleep caused by activation of central noradrenergic systems in mice |
| Q51550104 | Flumazenil reverses the decrease in the hypnotic activity of pentobarbital by social isolation stress: are endogenous benzodiazepine receptor ligands involved? |
| Q36304967 | Functionally differentiating two neuronal nitric oxide synthase isoforms through antisense mapping: evidence for opposing NO actions on morphine analgesia and tolerance |
| Q90241821 | Glucagon-like peptide-2 rescues memory impairments and neuropathological changes in a mouse model of dementia induced by the intracerebroventricular administration of streptozotocin |
| Q35616945 | Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. |
| Q72847892 | Head-twitch response induced by tyramine |
| Q35109065 | Hemokinin-1(4-11)-induced analgesia selectively up-regulates δ-opioid receptor expression in mice. |
| Q48847698 | Hepatobiliary effects of morphine are mediated in the brain |
| Q33929779 | Histamine mediates behavioural and metabolic effects of 3-iodothyroacetic acid, an endogenous end product of thyroid hormone metabolism. |
| Q48813752 | Hyperactivity of central noradrenergic and CRF systems is involved in social isolation-induced decrease in pentobarbital sleep |
| Q34023260 | Hyperbaric oxygen treatment induces a 2-phase antinociceptive response of unusually long duration in mice |
| Q35069667 | Hypothalamic GPR40 signaling activated by free long chain fatty acids suppresses CFA-induced inflammatory chronic pain |
| Q24301144 | Identification of 26RFa, a hypothalamic neuropeptide of the RFamide peptide family with orexigenic activity |
| Q37290396 | Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine |
| Q28379239 | Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release |
| Q48319054 | Identification of the receptor subtype involved in the analgesic effect of neurotensin |
| Q28830911 | In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer's Disease |
| Q47319838 | In vivo and ex vivo analyses of amyloid toxicity in the Tc1 mouse model of Down syndrome |
| Q36952288 | In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties |
| Q44538194 | In vivo stimulation of sympathetic nervous system modulates osteoblastic activity in mouse calvaria |
| Q38362785 | Inactivation of Gi proteins induces an antidepressant-like effect in the mouse forced-swimming test |
| Q34062512 | Increased methylation of the MOR gene proximal promoter in primary sensory neurons plays a crucial role in the decreased analgesic effect of opioids in neuropathic pain |
| Q43169496 | Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands |
| Q39615615 | Influence of catecholamines on dexamphetamine-induced changes in locomotor activity |
| Q51381491 | Influence of different histamine receptor agonists and antagonists on apomorphine-induced licking behavior in rat. |
| Q43084786 | Influence of potassium channel modulators on cognitive processes in mice. |
| Q36783997 | Inhibition of MAO-A and stimulation of behavioural activities in mice by the inactive prodrug form of the anti-influenza agent oseltamivir |
| Q37598746 | Inhibition of acute inflammation in the periphery by central action of salicylates |
| Q71673878 | Inhibitory effects of salmon calcitonin on the tail-biting and scratching behavior induced by substance P and three excitatory amino acids |
| Q51312235 | Injection of drugs into the cerebral ventricle of sheep |
| Q67556039 | Intensification of amphetamine-induced excitation by methysergide, a serotonergic receptor blocker |
| Q51526580 | Interactions of cocaine with morphine, U-50,488H and [D-Pen2, D-Pen5]enkaphalin. |
| Q36366085 | Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-6-deficient mice |
| Q51409146 | Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits. |
| Q85045686 | Intracerebroventricular administration of apelin-13 inhibits distal colonic transit in mice |
| Q53542960 | Intracerebroventricular ginsenosides are antinociceptive in proinflammatory cytokine-induced pain behaviors of mice. |
| Q46366822 | Intracerebroventricular guanine-based purines protect against seizures induced by quinolinic acid in mice |
| Q35754450 | Intracerebroventricular injection of anti-Fas activates the hypothalamus-pituitary-adrenal axis and induces peripheral interleukin-6 and serum amyloid A in mice: comparison with other ligands of the tumor necrosis factor/nerve growth factor receptor |
| Q40546664 | Intracerebroventricular interleukin-6, macrophage inflammatory protein-1β and IL-18: pyrogenic and PGE2-mediated? |
| Q67276978 | Intracerebroventricular treatment of mice with pertussis toxin induces hyperalgesia and enhances 3H-nitrendipine binding to synaptic membranes: similarity with morphine tolerance |
| Q42563153 | Investigation into atropine-induced antinociception |
| Q46090398 | Involvement of PLC-beta3 in the effect of morphine on memory retrieval in passive avoidance task |
| Q34633464 | Involvement of a NO-cyclic GMP-PKG signaling pathway in nitrous oxide-induced antinociception in mice |
| Q69370395 | Involvement of central histaminergic and cholinergic systems in the morphine-induced increase in blood-brain barrier permeability to sodium fluorescein in mice |
| Q44342915 | Involvement of central μ-opioid system in the scratching behavior in mice, and the suppression of it by the activation of κ-opioid system |
| Q38342129 | Involvement of kappa opioid receptors in the formalin-induced inhibition of analgesic tolerance to morphine via suppression of conventional protein kinase C activation |
| Q70061981 | Involvement of norepinephrine neurons in the hypothermia induced by intracerebroventricular administration of 6-hydroxydopamine in mice, evidenced by antidepressants |
| Q43509803 | Involvement of potassium channels in amitriptyline and clomipramine analgesia. |
| Q48678620 | Involvement of α(2)-adrenergic receptor in the regulation of the blood glucose level induced by immobilization stress |
| Q91635460 | Isorhynchophylline Exerts Antinociceptive Effects on Behavioral Hyperalgesia and Allodynia in a Mouse Model of Neuropathic Pain: Evidence of a 5-HT1A Receptor-Mediated Mechanism |
| Q36163631 | Kappa Opioid Receptor-Mediated Disruption of Novel Object Recognition: Relevance for Psychostimulant Treatment |
| Q43503068 | Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse |
| Q42083765 | L-arginine exerts a dual role in nociceptive processing in the brain: involvement of the kyotorphin-Met-enkephalin pathway and NO-cyclic GMP pathway |
| Q49021124 | L-type voltage-dependent calcium channels facilitate acetylation of histone H3 through PKCγ phosphorylation in mice with methamphetamine-induced place preference |
| Q41868169 | Leucine-enkephalin and methionine-enkephalin produce opposing effects on plasma corticosterone levels in ether-stressed mice |
| Q37010754 | Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception. |
| Q72637720 | Liver damage from narcotics in mice |
| Q28363126 | Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2), in mice |
| Q38312898 | Loss of muscarinic antinociception by antisense inhibition of M(1) receptors |
| Q47740126 | Lysophosphatidic acid induces anxiety-like behavior via its receptors in mice |
| Q28210294 | M1 receptor activation is a requirement for arecoline analgesia |
| Q35870857 | MDL 27,531 selectively reverses strychnine-induced seizures in mice |
| Q44331107 | Maintenance of acute morphine tolerance in mice by selective blockage of κ opioid receptors with norbinaltorphimine |
| Q72385476 | Mechanism of analgesic action of mesaconitine. I. Relationship between analgesic effect and central monoamines or opiate receptors |
| Q72858994 | Mechanism of chlorpromazine action on plasma glucose and cyclic amp levels |
| Q48505810 | Mediation of the hypoglycaemic effect of 5-hydroxytryptophan by a central nervous system action |
| Q48874402 | Meloxicam-loaded nanocapsules as an alternative to improve memory decline in an Alzheimer's disease model in mice: involvement of Na(+), K(+)-ATPase |
| Q88683310 | Membrane-Initiated Estrogen Receptor Signaling Mediates Metabolic Homeostasis via Central Activation of Protein Phosphatase 2A |
| Q42794550 | Memory restorative role of statins in experimental dementia: an evidence of their cholesterol dependent and independent actions |
| Q28207609 | Menthol: a natural analgesic compound |
| Q49082665 | Metabolism of the ethanolamine phosphoglycerides of mouse brain myelin and microsomes |
| Q41572234 | Metergoline elevates or reduces nociceptive thresholds in mice depending on test method and route of administration |
| Q34187516 | Methadone antinociception is dependent on peripheral opioid receptors |
| Q28362087 | Methylamine and benzylamine induced hypophagia in mice: modulation by semicarbazide-sensitive benzylamine oxidase inhibitors and aODN towards Kv1.1 channels |
| Q42275058 | Methylamine, but not ammonia, is hypophagic in mouse by interaction with brain Kv1.6 channel subtype |
| Q34538336 | Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2. |
| Q39176305 | Modification by monoamine oxidase inhibitors of the analgesic, hypothermic and toxic actions of morphine and pethidine in mice |
| Q71823029 | Modification of the anti-nociceptive activity of morphine by centrally administered ouabain and dopamine |
| Q48010033 | Modulation of PKA, PKC, CAMKII, ERK 1/2 pathways is involved in the acute antidepressant-like effect of (octylseleno)-xylofuranoside (OSX) in mice |
| Q41992250 | Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain |
| Q44164255 | Molecular chaperone heat shock protein 70 participates in the labile phase of the development of behavioural sensitization induced by a single morphine exposure in mice. |
| Q70171593 | Morphine exacerbates anaphylactic shock in mice by stimulating central opiate receptors |
| Q48407252 | Morphine suppression of ethanol withdrawal in mice |
| Q43867289 | Mouse light/dark box test reveals anxiogenic-like effects by activation of histamine H1 receptors |
| Q72490121 | Multi-dimensional analyses of behavior in mice treated with α-endorphin |
| Q39995189 | Multiple emulsions, a suitable vehicle to provide sustained release of cancer chemotherapeutic agents |
| Q44966063 | NDP-MSH inhibits neutrophil migration through nicotinic and adrenergic receptors in experimental peritonitis |
| Q35749650 | Naloxone acts as a potent analgesic in transgenic mouse models of sickle cell anemia |
| Q70109080 | Naloxone prevents the analgesic action of alpha-MSH in mice |
| Q48680800 | Naloxone reverses the inhibitory effects of dynorphin A on motor activity in the mouse |
| Q67490516 | Naloxone-induced analgesia in diabetic mice |
| Q43836491 | Narcotic agonists and antagonists as models for potential antidepressant drugs |
| Q69836985 | Narcotic antagonism of seizures induced by a dopamine-derived tetrahydroisoquinoline alkaloid |
| Q64068504 | Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice |
| Q47267653 | Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease |
| Q28257563 | Neurotoicity of apamin and MCD peptide upon central application |
| Q72660879 | Neurotoxins, protease inhibitors and histamine releasers in the venom of the Indian red scorpion (Buthus tamulus): Isolation and partial characterization |
| Q28343438 | Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice |
| Q48715462 | Nocistatin and nociceptin modulate c-Fos expression in the mice thalamus |
| Q34525251 | Nonpeptide small molecule agonist and antagonist original leads for neuropeptide FF1 and FF2 receptors |
| Q43558284 | Novel inhibitors of enkephalin-degrading enzymes. I: Inhibitors of enkephalinase by penicillins |
| Q28340574 | Novel inhibitors of enkephalin-degrading enzymes. II: N5'-substituted-4-thioxohydantoic acids as aminopeptidase inhibitors |
| Q35940344 | Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting κ opioid receptor antagonism |
| Q34247017 | Opiate antagonistic properties of an octapeptide somatostatin analog |
| Q43307682 | Opiate-like action of methionine-enkephalin in inhibiting morphine abstinence syndrome |
| Q36225640 | Opioid activity of spinally selective analogues of N-naphthoyl-β-naltrexamine in HEK-293 cells and mice |
| Q34244966 | Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series |
| Q35085111 | Oxidation-sensitive nociception involved in endometriosis-associated pain |
| Q50629865 | Pain regulation of endokinin A/B or endokinin C/D on chimeric peptide MCRT in mice. |
| Q51311690 | Passage of circulating adrenaline into perfused cerebral ventricles and subarachnoidal space. |
| Q28564943 | Peptides derived from the prohormone proNPQ/spexin are potent central modulators of cardiovascular and renal function and nociception |
| Q42261074 | Peripheral toxicity of hemicholinium-3 in mice |
| Q44333852 | Pharmacological characterization of [D-Ala2,Leu5,Ser6]enkephalin (DALES): antinociceptive actions at the δnon-complexed-opioid receptor |
| Q72565508 | Pharmacological characterization of the receptors involved in the apomorphine-induced polyphasic modifications of locomotor activity in mice |
| Q36610342 | Pharmacological effects of 3-iodothyronamine (T1AM) in mice include facilitation of memory acquisition and retention and reduction of pain threshold |
| Q36429323 | Pharmacological inhibition of TLR4-NOX4 signal protects against neuronal death in transient focal ischemia |
| Q44351544 | Pharmacological interaction of the calcium channel blockers verapamil and flunarizine with the opioid system |
| Q40017952 | Pharmacological properties of centrally administered ouabain and their modification by other drugs |
| Q43001927 | Pharmacological properties of centrally-administered agents which interfere with neurotransmitter function: a comparison with the central depressant effects of ouabain |
| Q42023907 | Pharmacological properties of pempidine (1:2:2:6:6-pentamethylpiperidine), a new ganglion-blocking compound |
| Q51149383 | Pharmacological significances of peptidase and proteinase in the brain. 4. Effect of bradykinin on the central nervous system and role of the enzyme inactivating bradykinin in mouse brain |
| Q46399968 | Pituitary adenylate cyclase-activating polypeptide inhibits food intake in mice through activation of the hypothalamic melanocortin system. |
| Q69503979 | Possible involvement of a dopaminergic pathway in the depressant effects of ouabain on the central nervous system |
| Q72040797 | Possible involvement of nitric oxide in quinolinic acid-induced convulsion in mice |
| Q48257933 | Possible neuronal mechanisms involved in neurotensin-induced catalepsy in mice |
| Q44344808 | Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors |
| Q44182452 | Potentiation of morphine analgesia by BQ123, an endothelin antagonist |
| Q28591665 | Potentiation of opioid analgesia in dopamine2 receptor knock-out mice: evidence for a tonically active anti-opioid system |
| Q48922339 | Potentiation of phenobarbital-induced anticonvulsant activity by pipecolic acid |
| Q24811385 | Pre-injury administration of morphine prevents development of neuropathic hyperalgesia through activation of descending monoaminergic mechanisms in the spinal cord in mice |
| Q36863382 | Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties |
| Q52025435 | Pro-cognitive activity induced in the rat by low doses of R-(+)-hyoscyamine. |
| Q46851153 | Protective effect of ((4-tert-butylcyclohexylidene) methyl) (4-methoxystyryl) sulfide, a novel unsymmetrical divinyl sulfide, on an oxidative stress model induced by sodium nitroprusside in mouse brain: involvement of glutathione peroxidase activity |
| Q42585845 | Putrescine catabolism in mammalian brain |
| Q48819905 | Rat supraoptic neurones: nucleolar changes in response to posterior pituitary extracts |
| Q64057527 | Rational design, cognition and neuropathology evaluation of QTC-4-MeOBnE in a streptozotocin-induced mouse model of sporadic Alzheimer's disease |
| Q44336278 | Redoubling the ring size of an endomorphin-2 analog transforms a centrally acting mu-opioid receptor agonist into a pure peripheral analgesic |
| Q72561684 | Reduction in ATP-sensitive potassium channel-mediated antinociception in diabetic mice |
| Q42883618 | Regulation of ryanodine receptors by dopamine D1 receptors during methamphetamine‐induced place conditioning |
| Q37705976 | Resveratrol-induced antinociception is involved in calcium channels and calcium/caffeine-sensitive pools |
| Q44330314 | Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice |
| Q48372847 | Reversal of the reserpine-induced ptosis by L-threo-3,4-dihydroxy-phenylserine (L-threo-DOPS), a (-)-norepinephrine precursor, and its potentiation by imipramine or nialamide |
| Q43178535 | Reversal of tolerance to the antitransit effects of morphine during acute intestinal inflammation in mice |
| Q36133099 | Reversible antisense inhibition of Shaker-like Kv1.1 potassium channel expression impairs associative memory in mouse and rat |
| Q44099995 | Rodent antinociception following acute treatment with different histamine receptor agonists and antagonists |
| Q54027566 | Role of ATP-sensitive K+ channels in antinociception induced by R-PIA, an adenosine A1 receptor agonist. |
| Q71614613 | Role of L-type calcium channels on yohimbine-precipitated clonidine withdrawal in vivo and in vitro |
| Q71338905 | Role of brain catecholamines and 5-hydroxytryptamine in morphine induced temperature changes in normal and tolerant rats and mice |
| Q40740621 | Role of central ATP-sensitive potassium channels in the hyperthermic effect of morphine in mice |
| Q35048685 | Role of descending noradrenergic system and spinal alpha2-adrenergic receptors in the effects of gabapentin on thermal and mechanical nociception after partial nerve injury in the mouse |
| Q42115852 | Role of histamine in rodent antinociception |
| Q43662399 | Role of hypothalamic-pituitary axis in morphine-induced alteration in thymic cell distribution using mu-opioid receptor knockout mice |
| Q41847231 | Role of muscarinic receptor subtypes in central antinociception |
| Q73964401 | Role of nitric oxide in diabetes-induced attenuation of antinociceptive effect of morphine in mice |
| Q44472575 | Role of platelet activating factor in triazolobenzodiazepines-induced retrograde amnesia |
| Q43189745 | Role of potassium channels in the antinociception induced by agonists of alpha2-adrenoceptors |
| Q31925777 | Selective inhibition of amine oxidases differently potentiate the hypophagic effect of benzylamine in mice |
| Q33911524 | Selective κ receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice. |
| Q43643813 | Selegiline reverses aβ₂₅₋₃₅-induced cognitive deficit in male mice. |
| Q42732287 | Selenofuranoside Ameliorates Memory Loss in Alzheimer-Like Sporadic Dementia: AChE Activity, Oxidative Stress, and Inflammation Involvement |
| Q48544854 | Sensitization of ethanol-induced place preference as a result of up-regulation of type 1 inositol 1,4,5-trisphosphate receptors in mouse nucleus accumbens |
| Q36274644 | Sex-specific mediation of opioid-induced hyperalgesia by the melanocortin-1 receptor |
| Q49137365 | Short-term behavioral effects of posterior pituitary peptides in mice |
| Q71364200 | Short-term manganese pretreatment partially protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity |
| Q48772612 | Sodium transport through the cerebral sodium-glucose transporter exacerbates neuron damage during cerebral ischaemia |
| Q41349220 | Some actions of delta-1 tetrahydrocannabinol and cannabidiol at cholinergic junctions |
| Q79222521 | Some biological properties of two fluoro-derivatives of tryptamine |
| Q39158674 | Some observations on the mechanism of benzodiazepine-barbiturate interactions in the mouse |
| Q41863608 | Some shortcomings of direct intraventricular injection in mice |
| Q54095325 | Spasmolytic and cholinergic blocking properties and toxicity of levomepate, I-tropine α-methyltropate |
| Q44334306 | Spinal GABA receptors mediate brain delta opioid analgesia in Swiss Webster mice |
| Q35100897 | Spinal alpha(2)-adrenergic and muscarinic receptors and the NO release cascade mediate supraspinally produced effectiveness of gabapentin at decreasing mechanical hypersensitivity in mice after partial nerve injury |
| Q37396218 | Steady-state level and turnover rate of the tripeptide Tyr-Gly-Gly as indexes of striatal enkephalin release in vivo and their reduction during pentobarbital anesthesia |
| Q48961230 | Stereoselective increase in cholinergic transmission by R-(+)-hyoscyamine |
| Q42196788 | Stereotaxic implantation of cannulae for subsequent drug administration into the third ventricles of conscious mice [proceedings] |
| Q48596436 | Streptozotocin Induces Mild Cognitive Impairment at Appropriate Doses in Mice as Determined by Long-Term Potentiation and the Morris Water Maze. |
| Q71153084 | Studies on the central effects of bulbocapnine |
| Q66692352 | Studies on the effects of histaminergic agents on seizure susceptibility in mice |
| Q39996018 | Study of the mechanisms of action of desipramine and chlorpromazine in reversing reserpine-induced hypothermia in mice. |
| Q34793265 | Subgroups among mu-opioid receptor agonists distinguished by ATP-sensitive K+ channel-acting drugs |
| Q67767964 | Suppression of ethanol withdrawal by dopamine |
| Q35001766 | Supraspinal administration of opioids with selectivity for mu-, delta- and kappa-opioid receptors produces analgesia in amphibians |
| Q44345360 | Supraspinal delta 1-opioid receptor-mediated antinociceptive properties of (-)-TAN-67 in diabetic mice |
| Q42083576 | Supraspinal-selective TRPV1 desensitization induced by intracerebroventricular treatment with resiniferatoxin. |
| Q33830017 | Supraspinally-administered agmatine attenuates the development of oral fentanyl self-administration |
| Q41434217 | Synaptosomal accumulation of intracerebral injected amino acids |
| Q50971812 | Synergistic effect of docosahexaenoic acid on anticonvulsant activity of valproic acid and lamotrigine in animal seizure models. |
| Q46457647 | Synthesis and antinociceptive effects of endomorphin-1 analogs with C-terminal linked by oligoarginine |
| Q35756505 | Synthesis and pharmacology of halogenated δ-opioid-selective [d-Ala(2)]deltorphin II peptide analogues |
| Q89507507 | Synthesis, Molecular Docking, and Preliminary Evaluation of 2-(1,2,3-Triazoyl)benzaldehydes As Multifunctional Agents for the Treatment of Alzheimer's Disease |
| Q44182810 | Targeted inactivation of the neurotensin type 1 receptor reveals its role in body temperature control and feeding behavior but not in analgesia |
| Q51204611 | Temperature changes produced by the injection of catecholamines and 5-hydroxytryptamine into the cerebral ventricles of the conscious mouse |
| Q39371102 | Tetrapeptide Endomorphin Analogs Require Both Full Length and Truncated Splice Variants of the Mu Opioid Receptor Gene Oprm1 for Analgesia |
| Q38262682 | The ON:OFF switch, σ1R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: implications in neurological disorders |
| Q44433754 | The Phospholipase C-IP3 Pathway is Involved in Muscarinic Antinociception |
| Q41987929 | The activation of supraspinal GPR40/FFA1 receptor signalling regulates the descending pain control system |
| Q34504856 | The acute antinociceptive effect of HBO₂ is mediated by a NO-cyclic GMP-PKG-KATP channel pathway in mice |
| Q50947616 | The analgesic effect of trans-resveratrol is regulated by calcium channels in the hippocampus of mice. |
| Q41603023 | The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor |
| Q59357319 | The antinociceptive effect of fluvoxamine |
| Q37190334 | The antinociceptive effects of ferulic acid on neuropathic pain: involvement of descending monoaminergic system and opioid receptors |
| Q35226846 | The assay of anti-pyretic drugs in mice, using intracerebral injection of pyretogenins |
| Q51750311 | The calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases. |
| Q34611911 | The central analgesia induced by antimigraine drugs is independent from Gi proteins: superiority of a fixed combination of indomethacin, prochlorperazine and caffeine, compared to sumatriptan, in an in vivo model |
| Q30489474 | The comparative pharmacology of some psychotropic drugs. |
| Q43822150 | The effect of 6-hydroxydopamine on the antinociceptive action of morphine |
| Q71572177 | The effect of 6-hydroxydopamine on the antinociceptive action of oxotremorine |
| Q69582011 | The effect of ?-amanitin on passive and active avoidance acquisition in mice |
| Q44335803 | The effect of chronic treatment with naltrindole, a selective delta-opioid antagonist, on mu-opioid receptor-mediated antinociception in diabetic mice |
| Q41726994 | The effect of intracerebroventricular administration of methionine-enkephalin on the stress-induced secretion of corticosterone in mice |
| Q39709879 | The effect of propranolol phentolamine and pimozide on drug-induced anorexia in the mouse |
| Q44342255 | The effects of dopamine D1 and D2 receptor antagonists on the rewarding effects of delta 1 and delta 2 opioid receptor agonists in mice |
| Q41357088 | The effects of intracerebroventricularly administered noradnamine and other sympathomimetic amines upon leptazol convulsions in mice |
| Q71275512 | The effects of intraventricular 6-hydroxydopamine and 5,6-dihydroxytryptamine on morphine induced locomotor stimulation |
| Q89440606 | The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology |
| Q37152489 | The growth factor progranulin attenuates neuronal injury induced by cerebral ischemia-reperfusion through the suppression of neutrophil recruitment |
| Q50432587 | The impact of scopolamine pretreatment on 3-iodothyronamine (T1AM) effects on memory and pain in mice |
| Q28379396 | The inhibitory effects of alpha(2)-adrenoceptor agonists on gastrointestinal transit during croton oil-induced intestinal inflammation |
| Q41363104 | The interactions of noradnamine and imipramine-like antidepressant drugs |
| Q51230311 | The intracerebral effects of noradrenaline and its modification by drugs in the mouse. |
| Q51220779 | The iron content of the brain of rats with choreiform movements |
| Q44345741 | The mu-opioid receptor is necessary for [D-Pen2,D-Pen5]enkephalin-induced analgesia |
| Q41899918 | The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes |
| Q42702715 | The noradrenaline precursor L-threo-3,4-dihydroxyphenylserine exhibits antinociceptive activity via central alpha-adrenoceptors in the mouse |
| Q89464718 | The orphan receptor GPR88 blunts the signaling of opioid receptors and multiple striatal GPCRs |
| Q44808718 | The reduction of food intake induced in mice by benzylamine and its derivatives |
| Q41355644 | The reversal of the central effects of noradrenaline by antidepressant drugs in mice |
| Q51426529 | The role of potassium channels in antihistamine analgesia. |
| Q34601489 | The synthetic TRH analogue taltirelin exerts modality-specific antinociceptive effects via distinct descending monoaminergic systems |
| Q48681606 | Thyrotropin-releasing hormone (TRH) improves survival in anaphylactic shock: A central effect mediated by the sympatho-adrenomedullary β-adrenoceptive system |
| Q48244715 | Tiagabine antinociception in rodents depends on GABA(B) receptor activation: parallel antinociception testing and medial thalamus GABA microdialysis |
| Q36770675 | Truncated mu opioid GPCR variant involvement in opioid-dependent and opioid-independent pain modulatory systems within the CNS. |
| Q36887197 | Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208 |
| Q54348613 | Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice. |
| Q74072554 | Up-regulation of brain N-methyl-D-aspartate receptors following multiple intracerebroventricular injections of [D-Pen2, D-Pen5] enkephalin and [D-Ala2, Glu4]deltorphin II in mice |
| Q45130083 | Utility of an elevated plus-maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock |
| Q42565331 | Vasopressin and stress-induced antinociception in the mouse |
| Q48421496 | Ventricular injection of nerve growth factor increases dopamine content in the striata of MPTP-treated mice |
| Q35544270 | Visceral hyperalgesia induced by forebrain-specific suppression of native Kv7/KCNQ/M-current in mice |
| Q35037821 | beta-Endorphin: cross tolerance to and cross physical dependence on morphine |
| Q34394408 | beta-endorphin is a potent analgesic agent |
| Q33829223 | cAMP/PKA-CREB-BDNF signaling pathway in hippocampus mediates cyclooxygenase 2-induced learning/memory deficits of rats subjected to chronic unpredictable mild stress |
| Q44348820 | mu-Opioid receptor-knockout mice: the role of mu-opioid receptor in gastrointestinal transit |
| Q49125329 | α-Adrenergic agents. 3. Behavioral effects of 2-aminotetralins |
| Q44334963 | δ-Opioid receptor agonist SNC80 induces central antinociception mediated by Ca2+ -activated Cl- channels |
| Q44333497 | κ-Opioid receptor agonists improve pirenzepine-induced disturbance of spontaneous alternation performance in the mouse |